EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Preclinical evaluation of targeted therapies for central nervous system metastases

Alexander J Pfeil iD, Joshua D Hale iD, Tiger S Zhang iD, Kentaro Wakayama, Isao Miyazaki, Igor Odintsov iD, Romel Somwar iD

Disease Models & Mechanisms · 01.09.2024 · 17 (9)

DOI: 10.1242/dmm.050836 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Disease Models & Mechanisms, online erschienen am 30.09.2024. Verfasst von Alexander J Pfeil und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Elevation Oncology, NCI NIH HHS, Merus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The central nervous system (CNS) represents a site of sanctuary for many metastatic tumors when systemic therapies that control the primary tumor cannot effectively penetrate intracranial lesions. Non-small cell lung cancers (NSCLCs) are the most likely of all neoplasms to metastasize to the brain, with up to 60% of patients developing CNS metastases during the disease process. Targeted therapies such as tyrosine kinase inhibitors (TKIs) have helped reduce lung cancer mortality but vary considerably in their capacity to control CNS metastases. The ability of these therapies to effectively target lesions in the CNS depends on several of their pharmacokinetic properties, including blood–brain barrier permeability, affinity for efflux transporters, and binding affinity for both plasma and brain tissue. Despite the existence of numerous preclinical models with which to characterize these properties, many targeted therapies have not been rigorously tested for CNS penetration during the discovery process, whereas some made it through preclinical testing despite poor brain penetration kinetics. Several TKIs have now been engineered with the characteristics of CNS-penetrant drugs, with clinical trials proving these efforts fruitful. This Review outlines the extent and variability of preclinical evidence for the efficacy of NSCLC-targeted therapies, which have been approved by the US Food and Drug Administration (FDA) or are in development, for treating CNS metastases, and how these data correlate with clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsMolecular Targeted TherapyHumansAnimalsDrug Evaluation, PreclinicalProtein Kinase InhibitorsBlood-Brain Barrier

Stichwörter der Autor:innen

Blood–brain barrierCentral nervous system metastasisNon-small cell lung cancerTargeted therapy

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • University of North Carolina School of Medicine, Chapel Hill, NC 27514, USA.
  • Taiho Pharmaceutical Co. Ltd. 3, Okubo, Tsukuba, Ibaraki 300-2611, Japan.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 021105, USA.
  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

ORCID-Profile: Alexander J Pfeil, Joshua D Hale, Tiger S Zhang, Igor Odintsov, Romel Somwar

Förderung

  • Elevation Oncology
  • NCI NIH HHS
  • Merus
  • Loxo Oncology
  • Helsinn
  • National Cancer Institute

Zitieren

APA

Pfeil, A. J., Hale, J. D., Zhang, T. S., Wakayama, K., Miyazaki, I., Odintsov, I., & Somwar, R. (2024). Preclinical evaluation of targeted therapies for central nervous system metastases. Disease Models & Mechanisms, 17(9). https://doi.org/10.1242/dmm.050836

Vancouver

Pfeil AJ, Hale JD, Zhang TS, Wakayama K, Miyazaki I, Odintsov I, et al. Preclinical evaluation of targeted therapies for central nervous system metastases. Disease Models & Mechanisms. 2024;17(9). doi:10.1242/dmm.050836

BibTeX
@article{Pfeil2024,
  author = {Pfeil, Alexander J and Hale, Joshua D and Zhang, Tiger S and Wakayama, Kentaro and Miyazaki, Isao and Odintsov, Igor and Somwar, Romel},
  title = {Preclinical evaluation of targeted therapies for central nervous system metastases},
  journal = {Disease Models & Mechanisms},
  year = {2024},
  volume = {17},
  number = {9},
  doi = {10.1242/dmm.050836}
}
Kostenlos starten →